Counterirritants and sensory profiling of pain-relieving patches
Main Article Content
Abstract
Introduction: Musculoskeletal pain is a common medical and socioeconomic problem worldwide. Treatment and management options most commonly include analgesics such as paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), and topical over-the-counter (OTC) preparations. Patients often use OTC topical analgesics owing to the benefits shown by clinical studies for the treatment and management of musculoskeletal injuries and disorders. The aim of this study was (1) to review the background, current understanding, and therapeutic usefulness of topical counterirritants for the management of musculoskeletal pain (2) and to evaluate the sensorial characteristics of two prototype patches containing counterirritants, designed to manage pain relief by delivering a warming or cooling sensation.
Methods: Detailed literature search was conducted in PubMed, Google Scholar, and Cochrane Library databases for this review. An expert sensory panel study comprising of ten trained sensory experts was conducted to evaluate the performance of prototype patches containing counterirritants for their sensory characteristics including overall sensation, cooling, warming, and tingling sensations, as well as functional parameters such as ease of application and removal, adhesive property, odor intensity, staining on clothes, residue or greasiness, and sweat/moistness on the skin after removal.
Results: Topical analgesics containing counterirritants like capsaicin, menthol, and salicylates produce analgesia by activating and then desensitizing epidermal nociceptors. Literature searches provide evidence for their use in the management of musculoskeletal pain. The expert sensory panel study showed that the sensations elicited by the prototype counterirritant patches were predominantly cooling, tingling, and low and short warming in nature, with strong adhesion, ease of application and removal, no staining, little to no residue and grease on the skin, and low lingering odor of menthol.
Conclusion: Literature search supports the use of counterirritants in the treatment of musculoskeletal pain like backache, strains, and sprains. In addition, the observations from the expert sensory panel study evaluating sensory and functional parameters of counterirritant patches showed that these patches provide predominantly cooling, tingling and low short lasting warming sensations with strong adhesion, no stain and little to no residue and grease. These results support their potential as a treatment modality with increased consumer acceptance, potentially increasing treatment adherence and maximizing the effectiveness of therapies. And may be used as part of multimodal pain treatment regimens for musculoskeletal conditions.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. WHO. Musculoskeletal health. 2022 [cited 2022 14 July]; Available from:
https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions.
II. El-Tallawy, S.N., et al., Management of Musculoskeletal Pain: An Update with Emphasis on Chronic Musculoskeletal Pain. Pain Ther, 2021. 10(1): p. 181-209.
III. Julie L. Olenak, N.C.P., "Chapter 7: Musculoskeletal Injuries and Disorders," Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care. 20th Edition ed. 2020.
IV. Anekar, A.A. and M. Cascella, WHO Analgesic Ladder, in StatPearls. 2022, StatPearls Publishing
Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL).
V. Jorge, L.L., C.C. Feres, and V.E. Teles, Topical preparations for pain relief: efficacy and patient adherence. J Pain Res, 2010. 4: p. 11-24.
VI. Qaseem, A., et al., Nonpharmacologic and Pharmacologic Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries in Adults: A Clinical Guideline From the American College of Physicians and American Academy of Family Physicians. Ann Intern Med, 2020. 173(9): p. 739-748.
VII. Lisi, D.M. OTC Transdermal Analgesic Patches in Pain Management. 2019 [cited 2022 14 July]; Available from: https://www.uspharmacist.com/article/otc-transdermal-analgesic-patches-in-pain-management.
VIII. Nalamachu, S. and J. Gudin, Characteristics of Analgesic Patch Formulations. J Pain Res, 2020. 13: p. 2343-2354.
IX. Mirel, S., et al., Topical patches as treatments for the management of patient musculoskeletal and neuropathic pain. Balneo Research Journal, 2017. 8(1): p. 21-25.
X. Malanga, G.A., N. Yan, and J. Stark, Mechanisms and efficacy of heat and cold therapies for musculoskeletal injury. Postgrad Med, 2015. 127(1): p. 57-65.
XI. Barkin, R.L., The pharmacology of topical analgesics. Postgrad Med, 2013. 125(4 Suppl 1): p. 7-18.
XII. Meeusen, R. and P. Lievens, The use of cryotherapy in sports injuries. Sports Med, 1986. 3(6): p. 398-414.
XIII. Melzack, R. and P.D. Wall, Pain mechanisms: a new theory. Science, 1965. 150(3699): p. 971-9.
XIV. Fedorczyk, J., The role of physical agents in modulating pain. J Hand Ther, 1997. 10(2): p. 110-21.
XV. Feucht, C.L. and D.R. Patel, Analgesics and anti-inflammatory medications in sports: use and abuse. Pediatr Clin North Am, 2010. 57(3): p. 751-74.
XVI. Knotkova, H., M. Pappagallo, and A. Szallasi, Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain, 2008. 24(2): p. 142-54.
XVII. Stanos, S.P., Topical agents for the management of musculoskeletal pain. J Pain Symptom Manage, 2007. 33(3): p. 342-55.
XVIII. Derry, S., et al., Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. Cochrane Database Syst Rev, 2017. 5(5): p. Cd008609.
XIX. Baranidharan, G., S. Das, and A. Bhaskar, A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain. Ther Adv Neurol Disord, 2013. 6(5): p. 287-97.
XX. Jordan, K.M., et al., EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis, 2003. 62(12): p. 1145-55.
XXI. Kloppenburg, M., et al., 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis, 2019. 78(1): p. 16-24.
XXII. Mason, L., et al., Systematic review of topical capsaicin for the treatment of chronic pain. Bmj, 2004. 328(7446): p. 991.
XXIII. Zhang, W.Y. and A. Li Wan Po, The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol, 1994. 46(6): p. 517-22.
XXIV. Akgol Gur, S.T., et al., Topical capsaicin versus topical ibuprofen in acute musculoskeletal injuries: A randomized, double-blind trial. Hong Kong Journal of Emergency Medicine, 2020: p. 1024907920975368.
XXV. Warnecke, J.M., et al., Evaluation of changes in the haemoglobin of skin and muscle tissue of the calf, as induced by topical application of a nonivamide/nicoboxil cream. Can J Physiol Pharmacol, 2014. 92(2): p. 149-54.
XXVI. Gaubitz, M., et al., Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial. Eur J Pain, 2016. 20(2): p. 263-73.
XXVII. Blahova, Z., et al., Nicoboxil/nonivamide cream effectively and safely reduces acute nonspecific low back pain - a randomized, placebo-controlled trial. J Pain Res, 2016. 9: p. 1221-1230.
XXVIII. Solov'eva, E.Y. and O.A. Baranova, [Real-world clinical efficacy assessment of Kapsikam a combined topical medication based on nonivamide synthetic capsaicin analog in patients with acute nonspecific musculoskeletal back pain: LOCUS observational study outcomes]. Zh Nevrol Psikhiatr Im S S Korsakova, 2021. 121(10): p. 72-77.
XXIX. Horváth, K., et al., Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma. Neuropeptides, 2014. 48(6): p. 371-8.
XXX. EFSA, Flavouring Group Evaluation 86,(FGE. 86)‐Consideration of aliphatic and aromatic amines and amides evaluated by JECFA (65th meeting)‐Scientific Opinion of the Panel on Food Additives‐Flavourings, Processing Aids and Materials in Contact with Food. EFSA Journal, 2008. 6(11): p. 745.
XXXI. SIGN. Scottish Intercollegiate Guidelines Network (SIGN), Management of chronic pain, A national clinical guideline. SIGN 136. 2013 [cited 2022 14 July]; Available from: https://www.sign.ac.uk/media/1108/sign136_2019.pdf.
XXXII. Derry, S., et al., Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults. Cochrane Database Syst Rev, 2014. 2014(11): p. Cd007403.
XXXIII. Mason, L., et al., Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. Bmj, 2004. 328(7446): p. 995.
XXXIV. Rutner, M., et al., [Therapy of rheumatic disease with a hydroxyethylsalicylate gel. Results of 2 clinical studies of effectiveness and bioavailability]. Fortschr Med, 1995. 113(8): p. 111-3.
XXXV. Ginsberg, F. and J.P. Famaey, A double-blind study of topical massage with Rado-Salil ointment in mechanical low-back pain. J Int Med Res, 1987. 15(3): p. 148-53.
XXXVI. FDA, Skin protectant drug products for over-the-counter human use; final monograph. Final rule. Fed Regist, 2003. 68(107): p. 33362-81.
XXXVII. Pergolizzi, J.V., Jr., et al., The role and mechanism of action of menthol in topical analgesic products. J Clin Pharm Ther, 2018. 43(3): p. 313-319.
XXXVIII. Stanos, S., M. Tyburski, and S. Parikh, 37 - Minor and Short-Acting Analgesics, Including Opioid Combination Products. 2014. p. 508-529.e6.
XXXIX. Xu, H., N.T. Blair, and D.E. Clapham, Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloid-independent mechanism. J Neurosci, 2005. 25(39): p. 8924-37.
XL. Page, P. and L. Alexander, The clinical effectiveness of Biofreeze® topical analgesic on musculoskeletal pain: a systematic review. J Perform Health Res, 2017. 1.
XLI. Sundstrup, E., et al., Acute effect of topical menthol on chronic pain in slaughterhouse workers with carpal tunnel syndrome: triple-blind, randomized placebo-controlled trial. Rehabil Res Pract, 2014. 2014: p. 310913.
XLII. Keshavarzian, S. and N. Shahgholian, Comparison of the Effect of Topical Application of Rosemary and Menthol for Musculoskeletal Pain in Hemodialysis Patients. Iran J Nurs Midwifery Res, 2017. 22(6): p. 436-441.
XLIII. Johar, P., et al., A comparison of topical menthol to ice on pain, evoked tetanic and voluntary force during delayed onset muscle soreness. Int J Sports Phys Ther, 2012. 7(3): p. 314-22.
XLIV. Gudin, J.A., D.T. Dietze, and P.L. Hurwitz, Improvement of Pain and Function After Use of a Topical Pain Relieving Patch: Results of the RELIEF Study. J Pain Res, 2020. 13: p. 1557-1568.
XLV. Higashi, Y., T. Kiuchi, and K. Furuta, Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Clin Ther, 2010. 32(1): p. 34-43.
XLVI. Elawa, S., et al., The microvascular response in the skin to topical application of methyl nicotinate: Effect of concentration and variation between skin sites. Microvasc Res, 2019. 124: p. 54-60.
XLVII. Colizzi, A.D., F.; Marchionni, A., Evaluation of therapeutic activity in microtraumatology of the athlete and of the prophylactic curative action of pathological situations in the musculo skeletal apparatus secondary to physical effort of a preparation in ointment form containing the active principles methyl nicotinate and glycol salicylate. Gazzetta Medica Italiana Archivio per le Scienze Mediche, 1988. 147(3): p. 55-60.
XLVIII. Pabst, H., et al., Combination of comfrey root extract plus methyl nicotinate in patients with conditions of acute upper or low back pain: a multicentre randomised controlled trial. Phytother Res, 2013. 27(6): p. 811-7.
XLIX. Losi, S., et al., The role of patient preferences in adherence to treatment in chronic disease: a narrative review. Drug Target Insights, 2021. 15: p. 13-20.
L. Kathe, K. and H. Kathpalia, Film forming systems for topical and transdermal drug delivery. Asian J Pharm Sci, 2017. 12(6): p. 487-497.
LI. Romita, P., et al., Contact dermatitis due to transdermal therapeutic systems: a clinical update. Acta Biomed, 2018. 90(1): p. 5-10.
LII. FDA. Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs-Draft Guidance for Industry. 2018 [cited 2022 14 July]; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas.
LIII. Yang, X. and R.A. Boyle, Chapter 3 - Sensory Evaluation of Oils/Fats and Oil/Fat–Based Foods, in Oxidative Stability and Shelf Life of Foods Containing Oils and Fats, M. Hu and C. Jacobsen, Editors. 2016, AOCS Press. p. 157-185.
LIV. Harry T. Lawless, H.H., Sensory Evaluation of Food: Principles and Practices. 2010: Springer New York, NY.
LV. Hootman, R.C. Manual on descriptive analysis testing for sensory evaluation. 1992. ASTM Philadelphia, PA:.
LVI. Worch, T., S. Lê, and P. Punter, How reliable are the consumers? Comparison of sensory profiles from consumers and experts. Food quality and preference, 2010. 21(3): p. 309-318.
LVII. Williams, E.J., Experimental designs balanced for the estimation of residual effects of treatments. Australian Journal of Chemistry, 1949. 2(2): p. 149-168.
LVIII. Kuesten, C., J. Bi, and Y. Feng, Exploring taffy product consumption experiences using a multi-attribute time–intensity (MATI) method. Food Quality and Preference, 2013. 30(2): p. 260-273.